LLY

902.74

-0.9%↓

UNH

596.8

+0.31%↑

NVO

131.05

+0.18%↑

JNJ

164.37

-0.29%↓

ABBV

193.18

+0.34%↑

LLY

902.74

-0.9%↓

UNH

596.8

+0.31%↑

NVO

131.05

+0.18%↑

JNJ

164.37

-0.29%↓

ABBV

193.18

+0.34%↑

LLY

902.74

-0.9%↓

UNH

596.8

+0.31%↑

NVO

131.05

+0.18%↑

JNJ

164.37

-0.29%↓

ABBV

193.18

+0.34%↑

LLY

902.74

-0.9%↓

UNH

596.8

+0.31%↑

NVO

131.05

+0.18%↑

JNJ

164.37

-0.29%↓

ABBV

193.18

+0.34%↑

LLY

902.74

-0.9%↓

UNH

596.8

+0.31%↑

NVO

131.05

+0.18%↑

JNJ

164.37

-0.29%↓

ABBV

193.18

+0.34%↑

Strona główna・Stock List・Halozyme Therapeutics Inc

Halozyme Therapeutics Inc

Closed

Sector Healthcare

59.21 -2.85

Buy Sell

Overview

Share price change

24h

Current

Min

59.01

Max

59.43

Key metrics
By Trading Economics
Income	16M 93M
Sales	35M 231M
P/E Sector Avg	21.73 103.001
EPS	0.91
Profit margin	40.366
Employees	373
EBITDA	22M 143M

Recommendations
By TipRanks
Recommendations	Buy
12 Months Forecast	+1.89 upside

Dividends
By Dow Jones
Next Earnings	4 lis 2024

Market Stats
By TradingEconomics
Market Cap	262M 8.1B
Previous open	62.06
Previous close	59.21

News Sentiment

By Acuity

50%

114 / 365 Ranking in Healthcare

Technical Score

By Trading Central

Confidence

Very Strong Bearish Evidence

N/A / 62.05 Support & Resistance

Halozyme Therapeutics Inc Chart

Related News

6 wrz 2024, 22:41 UTC

Market Talk

KinderCare and StandardAero File for IPOs -- Market Talk

6 wrz 2024, 21:18 UTC

Top News

Hiring Softened This Summer, Teeing Up Fed Rate Cuts -- Update

6 wrz 2024, 21:05 UTC

Top News

U.S. Tells Allies Iran Has Sent Ballistic Missiles to Russia, European and U.S. Officials Say -- 4th Update

6 wrz 2024, 20:50 UTC

Market Talk

Auto & Transport Roundup: Market Talk

6 wrz 2024, 20:39 UTC

Earnings

Update: NIO Stock Caught an Upgrade. Shares Rose. -- Barrons.com

6 wrz 2024, 20:35 UTC

Top News

Stocks Extend Ugly Week of Losses Amid Economic Uncertainty -- WSJ

6 wrz 2024, 20:34 UTC

Top News

U.S. Tells Allies Iran Has Sent Ballistic Missiles to Russia, European and U.S. Officials Say -- 3rd Update

6 wrz 2024, 20:11 UTC

Top News

Stock Indexes Close Lower After Mixed Jobs Report -- WSJ

6 wrz 2024, 19:51 UTC

Top News

U.S. Tells Allies Iran Has Sent Ballistic Missiles to Russia, European and U.S. Officials Say -- WSJ

6 wrz 2024, 19:16 UTC

Market Talk

U.S. Natural Gas Futures Hold Gains -- Market Talk

6 wrz 2024, 19:14 UTC

Market Talk

Oil Futures Extend Losses on Demand Concerns -- Market Talk

6 wrz 2024, 19:01 UTC

Market Talk

Gold Slips on Prevailing Uncertainty -- Market Talk

6 wrz 2024, 18:27 UTC

Top News

JPMorgan Plans to Report Customers Who Exploited TikTok 'Glitch' to Authorities -- WSJ

6 wrz 2024, 18:25 UTC

Market Talk

Broadcom Growth Views Conservative Amid AI Investments -- Market Talk

6 wrz 2024, 18:15 UTC

Top News

U.S. Tells Allies Iran Has Sent Ballistic Missiles to Russia, European and U.S. Officials Say -- Update

6 wrz 2024, 18:12 UTC

Top News

Nasdaq Falls 2.5%, Leads Losses After Mixed Jobs Report -- WSJ

6 wrz 2024, 17:44 UTC

Market Talk

Labor Costs Represent Diminishing Risk To Canada CPI, CIBC's Shenfeld Says -- Market Talk

6 wrz 2024, 17:30 UTC

Market Talk

U.S Oil Rig Count Unchanged at 483 -- Market Talk

6 wrz 2024, 17:30 UTC

Top News

Boeing's Starliner Is Returning to Earth Without Its Crew -- WSJ

6 wrz 2024, 17:27 UTC

Top News

Hiring Softened This Summer, Teeing Up Fed Rate Cuts -- WSJ

6 wrz 2024, 17:00 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

6 wrz 2024, 17:00 UTC

Market Talk

Mexican Inflation Seen Easing in August -- Market Talk

6 wrz 2024, 16:36 UTC

Market Talk

Oil Futures Fall as U.S. Jobs Report Sinks In -- Market Talk

6 wrz 2024, 16:35 UTC

Earnings

Hot Stocks

Stocks to Watch Friday: Broadcom, Nvidia, UiPath, Smith & Wesson -- WSJ

6 wrz 2024, 16:33 UTC

Acquisitions, Mergers, Takeovers

Salesforce Stock Is on Pace for Longest Losing Streak Since 2008. An Acquisition Isn't Helping. -- Barrons.com

6 wrz 2024, 16:20 UTC

Market Talk

Earnings

Tech, Media & Telecom Roundup: Market Talk

6 wrz 2024, 16:20 UTC

Earnings

Oracle Profit, Revenue Set to Rise in 1Q -- Earnings Preview

6 wrz 2024, 16:20 UTC

Market Talk

Auto & Transport Roundup: Market Talk

6 wrz 2024, 16:20 UTC

Market Talk

Basic Materials Roundup: Market Talk

6 wrz 2024, 16:20 UTC

Market Talk

Energy & Utilities Roundup: Market Talk

Peer Comparison

Price change

Halozyme Therapeutics Inc Forecast

Price Target

By TipRanks

1.89% upside

12 Months Forecast

Average 60.33 USD 1.89%

High 72 USD

Low 51 USD

Based on 10 Wall Street analysts offering 12 month price targets forHalozyme Therapeutics Inc - Dist in the last 3 months.

Rating Consensus

By TipRanks

Buy

10 ratings

Buy

Hold

Sell

Based on 10 analysts giving stock ratings to Halozyme Therapeutics Inc - Dist in the past 3 months.

Technical Score

By Trading Central

N/A / 62.05Support & Resistance

Recent bearish events outweigh bullish events.

All events are bullish.

Sentiment

By Acuity

114 / 365 Ranking in Healthcare

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

About Halozyme Therapeutics Inc

Halozyme Therapeutics, Inc. is a biopharma technology platform company. The Company licenses its technology to biopharmaceutical companies to collaboratively develop products that combine its ENHANZE drug delivery technology with the collaborators' compounds. The Company's lead enzyme, rHuPH20, is used to facilitate the delivery of injected drugs and fluids. The Company's approved product and its collaborators’ approved products and product candidates are based on rHuPH20, a patented recombinant human hyaluronidase enzyme. The Company's lead product, Hylenex recombinant, is a formulation of rHuPH20 that facilitates subcutaneous fluid administration for achieving hydration, to increase the dispersion and absorption of other injected drugs and, in subcutaneous urography, to improve resorption of radiopaque agents. Its pipeline products include Herceptin SC, HYQVIA, DARZALEX and others.